Erudio Healtherudio.com
Sponsor
Kura Oncology trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Kura Oncology: KOMET-017. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Kura Oncology, Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| KOMET-017 NCT07007312 · Kura Oncology, Inc. | untreated NPM1-mutated or KMT2A-rearranged acute myeloid leukemia | Phase 3 | 34 | 7 | Focused | Oct 19, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| KOMET-001 NCT04067336 · Kura Oncology, Inc. DeepView → | relapsed or refractory acute myeloid leukemia | Phase 1/Phase 2 | Deep | View | |||
| KOMET-007 NCT05735184 · Kura Oncology, Inc. DeepView → | NPM1-mutated or KMT2Ar acute myeloid leukemia | Phase 1 | Deep | View | |||